Compare RNW & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNW | SRPT |
|---|---|---|
| Founded | 2011 | 1980 |
| Country | United Kingdom | United States |
| Employees | 4336 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | N/A | 2000 |
| Metric | RNW | SRPT |
|---|---|---|
| Price | $6.18 | $16.77 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 29 |
| Target Price | $7.00 | ★ $25.85 |
| AVG Volume (30 Days) | 1.2M | ★ 3.1M |
| Earning Date | 06-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.99 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.50 | N/A |
| P/E Ratio | $14.63 | ★ $5.61 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $4.39 | $14.68 |
| 52 Week High | $8.24 | $25.32 |
| Indicator | RNW | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 52.42 | 51.19 |
| Support Level | $5.95 | $15.55 |
| Resistance Level | $6.33 | $18.16 |
| Average True Range (ATR) | 0.18 | 0.82 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 67.86 | 68.81 |
ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.